Armistice Capital’s ABVC BioPharma ABVC Stock Holding History

Armistice Capital’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-109,275	Closed	-$1.16K	–	198
2022 Q2	$1.16K	Buy	+109,275	New	+$2.21M	0.02%	124

Other funds holding ABVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital's ABVC Position: Q3 2022 in Review

Armistice Capital sold out of ABVC BioPharma (ABVC) in Q3 2022, closing a stake of 109,275 shares — an estimated $1.16K sold.

Armistice Capital first reported a position in ABVC in Q2 2022 and held it in 1 quarter. The position peaked at $1.16K in Q2 2022. 11 funds tracked by Wall St. Rank hold ABVC as of Q3 2022.

Armistice Capital reported no remaining ABVC BioPharma position as of Q3 2022 after selling out during the quarter.
Armistice Capital sold 109,275 ABVC BioPharma shares in Q3 2022, an estimated $1.16K.
Armistice Capital first reported a position in ABVC BioPharma in Q2 2022 and held it in 1 quarter.
Armistice Capital's ABVC BioPharma position peaked at $1.16K in Q2 2022.
11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q3 2022.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.